TY - JOUR
T1 - Association of Serum Pyridoxal Phosphate Levels with Established Status Epilepticus
AU - Rubinos, Clio
AU - Bruzzone, Maria Jose
AU - Blodgett, Courtney
AU - Tsai, Carolyn
AU - Patel, Puja
AU - Hianik, Rachel
AU - Jadav, Rakesh
AU - Boudesseul, Jordane
AU - Liu, Chuning
AU - Zhu, Hongtu
AU - Wilson, Susan E.
AU - Olm-Shipman, Casey
AU - Meeker, Rick
AU - Hirsch, Lawrence J.
N1 - Funding Information:
We acknowledge the editorial assistance of the North Carolina Translational and Clinical Sciences Institute and i2b2 software, which was used in conducting the study; both are supported by the National Center for Advancing Translational Sciences of the National Institutes of Health through grant award UL1TR002489.
Funding Information:
No author declared any conflict of interest pertaining to this article, and all reported items pertain to outside of this work. Drs. Tsai, Jadav, Bruzzone, Olm-Shipman, Wilson, and Meeker and Mrs. Patel, Mrs. Hainik, and Mrs. Blodgett did not report any disclosures. Dr. Rubinos receives funding from the Physician in Training Program (UNC School of Medicine). Dr. Hirsch reports research support to Yale University for investigator-initiated studies from the Daniel Raymond Wong Neurology Research Fund at Yale; royalties from Wiley and Wolters-Kluwer; personal fees from Ceribell, Monteris, Neuropace, Aquestive, Medtronic, UCB, Marinus, Accure, Natus, Neurelis, and Eisai; and speaking honoraria from Neuropace, Natus, and UCB.
Publisher Copyright:
© 2022, Springer Science+Business Media, LLC, part of Springer Nature and Neurocritical Care Society.
PY - 2022
Y1 - 2022
N2 - Background: The objective of this study was to determine the prevalence of pyridoxine deficiency, measured by pyridoxal phosphate (PLP) levels, in patients admitted to the hospital with established (benzodiazepine-resistant) status epilepticus (SE) (eSE) and to compare to three control groups: intensive care unit (ICU) patients without SE (ICU-noSE), non-ICU inpatients without SE (non-ICU), and outpatients with or without a history of epilepsy (outpatient). Methods: This retrospective cohort study was conducted at the University of North Carolina Hospitals and Yale New Haven Hospital. Participants included inpatients and outpatients who had serum PLP levels measured during clinical care between January 2018 and March 2021. The first PLP level obtained was categorized as normal (> 30 nmol/L), marginal (≤ 30 nmol/L), deficient (≤ 20 nmol/L), and severely deficient (≤ 5 nmol/L). Results: A total of 293 patients were included (52 eSE, 40 ICU-noSE, 44 non-ICU, and 157 outpatient). The median age was 55 (range 19–99) years. The median PLP level of the eSE group (12 nmol/L) was lower than that of the ICU-noSE (22 nmol/L, p = 0.003), non-ICU (16 nmol/L, p = 0.05), and outpatient groups (36 nmol/L, p < 0.001). Patients with eSE had a significantly higher prevalence of marginal and deficient PLP levels (90 and 80%, respectively) than patients in each of the other three groups (ICU-noSE: 70, 50%; non-ICU: 63, 54%; outpatient: 38, 21%). This significantly higher prevalence persisted after correcting for critical illness severity and timing of PLP level collection. Conclusions: Our study confirms previous findings indicating a high prevalence of pyridoxine deficiency (as measured by serum PLP levels) in patients with eSE, including when using a more restricted definition of pyridoxine deficiency. Prevalence is higher in patients with eSE than in patients in all three control groups (ICU-noSE, non-ICU, and outpatient). Considering the role of pyridoxine, thus PLP, in the synthesis of γ-aminobutyric acid and its easy and safe administration, prospective studies on pyridoxine supplementation in patients with eSE are needed.
AB - Background: The objective of this study was to determine the prevalence of pyridoxine deficiency, measured by pyridoxal phosphate (PLP) levels, in patients admitted to the hospital with established (benzodiazepine-resistant) status epilepticus (SE) (eSE) and to compare to three control groups: intensive care unit (ICU) patients without SE (ICU-noSE), non-ICU inpatients without SE (non-ICU), and outpatients with or without a history of epilepsy (outpatient). Methods: This retrospective cohort study was conducted at the University of North Carolina Hospitals and Yale New Haven Hospital. Participants included inpatients and outpatients who had serum PLP levels measured during clinical care between January 2018 and March 2021. The first PLP level obtained was categorized as normal (> 30 nmol/L), marginal (≤ 30 nmol/L), deficient (≤ 20 nmol/L), and severely deficient (≤ 5 nmol/L). Results: A total of 293 patients were included (52 eSE, 40 ICU-noSE, 44 non-ICU, and 157 outpatient). The median age was 55 (range 19–99) years. The median PLP level of the eSE group (12 nmol/L) was lower than that of the ICU-noSE (22 nmol/L, p = 0.003), non-ICU (16 nmol/L, p = 0.05), and outpatient groups (36 nmol/L, p < 0.001). Patients with eSE had a significantly higher prevalence of marginal and deficient PLP levels (90 and 80%, respectively) than patients in each of the other three groups (ICU-noSE: 70, 50%; non-ICU: 63, 54%; outpatient: 38, 21%). This significantly higher prevalence persisted after correcting for critical illness severity and timing of PLP level collection. Conclusions: Our study confirms previous findings indicating a high prevalence of pyridoxine deficiency (as measured by serum PLP levels) in patients with eSE, including when using a more restricted definition of pyridoxine deficiency. Prevalence is higher in patients with eSE than in patients in all three control groups (ICU-noSE, non-ICU, and outpatient). Considering the role of pyridoxine, thus PLP, in the synthesis of γ-aminobutyric acid and its easy and safe administration, prospective studies on pyridoxine supplementation in patients with eSE are needed.
KW - Benzodiazepine-resistant seizures
KW - Established status epilepticus
KW - Pyridoxal phosphate deficiency
KW - Pyridoxine deficiency
KW - Vitamin B6 levels
UR - https://hdl.handle.net/20.500.12724/17684
UR - https://www.mendeley.com/catalogue/e7b1bdc2-9f8c-35ff-966e-eb69f98c1e23/
U2 - 10.1007/s12028-022-01579-z
DO - 10.1007/s12028-022-01579-z
M3 - Artículo (Contribución a Revista)
C2 - 36071331
AN - SCOPUS:85137523337
SN - 1541-6933
VL - 38
SP - 41
EP - 51
JO - Neurocritical Care
JF - Neurocritical Care
IS - 1
ER -